420 related articles for article (PubMed ID: 31068044)
21. Moxetumomab pasudotox for the treatment of hairy cell leukemia.
Janus A; Robak T
Expert Opin Biol Ther; 2019 Jun; 19(6):501-508. PubMed ID: 31045462
[No Abstract] [Full Text] [Related]
22. Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia.
Abou Dalle I; Ravandi F
Expert Rev Hematol; 2019 Sep; 12(9):707-714. PubMed ID: 31298972
[No Abstract] [Full Text] [Related]
23. Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.
Nobre CF; Newman MJ; DeLisa A; Newman P
Cancer Chemother Pharmacol; 2019 Aug; 84(2):255-263. PubMed ID: 31134324
[TBL] [Abstract][Full Text] [Related]
24. Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies.
Siddiqui R; Sardar M; Shahzad M; Jose J; Selene I; Shah Z; Qureshi A; Shafqat M; Kashif R; Ahmad M; Mejia-Garcia A; Anwer F
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):659-666. PubMed ID: 34275772
[TBL] [Abstract][Full Text] [Related]
25. Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.
Paillassa J; Maitre E; Troussard X
Curr Oncol Rep; 2022 Sep; 24(9):1133-1143. PubMed ID: 35403971
[TBL] [Abstract][Full Text] [Related]
26. Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use.
Kang C
Clin Drug Investig; 2021 Sep; 41(9):829-834. PubMed ID: 34383256
[TBL] [Abstract][Full Text] [Related]
27. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
[TBL] [Abstract][Full Text] [Related]
28. Expression of the muscle-associated gene MYF6 in hairy cell leukemia.
Arons E; Zhou H; Sokolsky M; Gorelik D; Potocka K; Davies S; Fykes E; Still K; Edelman DC; Wang Y; Meltzer PS; Raffeld M; Wiestner A; Xi L; Wang HW; Stetler-Stevenson M; Yuan C; Kreitman RJ
PLoS One; 2020; 15(2):e0227586. PubMed ID: 32040482
[TBL] [Abstract][Full Text] [Related]
29. Advances in the Treatment of Hairy Cell Leukemia Variant.
Tran J; Gaulin C; Tallman MS
Curr Treat Options Oncol; 2022 Jan; 23(1):99-116. PubMed ID: 35178674
[TBL] [Abstract][Full Text] [Related]
30. Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox.
Robak T; Janus A; Jamroziak K; Tiacci E; Kreitman RJ
J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34202156
[TBL] [Abstract][Full Text] [Related]
31. The pharmacological management of hairy cell leukemia.
Ramos Perez J; Ravandi-Kashani F
Expert Opin Pharmacother; 2020 Aug; 21(11):1337-1344. PubMed ID: 32378970
[TBL] [Abstract][Full Text] [Related]
32. Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders.
Maitre E; Paillassa J; Troussard X
Front Oncol; 2022; 12():1068981. PubMed ID: 36620555
[TBL] [Abstract][Full Text] [Related]
33. Hairy Cell Leukaemia: From Hairy Beginnings to a BRAF New World.
Dearden C; Iyengar S
Br J Haematol; 2020 Nov; 191(4):527-534. PubMed ID: 33190264
[TBL] [Abstract][Full Text] [Related]
34. Novel therapeutics in hairy cell leukemia.
Sarvaria A; Saven A
Expert Rev Hematol; 2019 Nov; 12(11):983-987. PubMed ID: 31380711
[No Abstract] [Full Text] [Related]
35. Approach to the patient after relapse of hairy cell leukemia.
Kreitman RJ; Fitzgerald DJ; Pastan I
Leuk Lymphoma; 2009 Oct; 50 Suppl 1(Suppl 1):32-7. PubMed ID: 19814696
[TBL] [Abstract][Full Text] [Related]
36. Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
Troussard X; Maître E; Cornet E
Am J Hematol; 2022 Feb; 97(2):226-236. PubMed ID: 34710243
[TBL] [Abstract][Full Text] [Related]
37. [Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?].
Troussard X; Maitre E; Paillassa J
Bull Cancer; 2021; 108(7-8):771-778. PubMed ID: 34023063
[TBL] [Abstract][Full Text] [Related]
38. Hairy Cell Leukemia: Where Are We in 2023?
Mendez-Hernandez A; Moturi K; Hanson V; Andritsos LA
Curr Oncol Rep; 2023 Aug; 25(8):833-840. PubMed ID: 37097545
[TBL] [Abstract][Full Text] [Related]
39. Hairy cell leukemia: a brief update on current knowledge and treatment prospects.
Puła A; Robak T
Curr Opin Oncol; 2021 Sep; 33(5):412-419. PubMed ID: 34264896
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
